Preferred Label : Tibremciclib;
NCIt synonyms : CDK4/6 Inhibitor BPI-16350;
NCIt definition : An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and
6 (CDK6), with potential antineoplastic activity. Upon administration, tibremciclib
selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma
protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and
leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell
proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many
tumor cell types and play a key role in the regulation of both cell cycle progression
from the G1-phase into the S-phase and tumor cell proliferation.;
UNII : CRB7BT5JDQ;
CAS number : 2397678-18-9;
Molecule name : BPI-16350; BPI 16350;
NCI Metathesaurus CUI : CL1921934;
Origin ID : C203165;
UMLS CUI : C5909045;
Semantic type(s)
- concept_is_in_subset
- has_target
